research Low Dose Oral Minoxidil in Androgenetic Alopecia
The 2.5 mg dose of oral minoxidil is more effective for hair growth in androgenetic alopecia.
Search
forProducts matching "mg"
Tracking 60 products like 191 Toby Horsetail Supplement, 218 Mega We Care Zincomin, 254 Advanced Hair Revitalizing Formula, 204 Nutriv Biotin Zinc Plus and 193 Vistra L-Cysteine Plus Biotin from by companies like ZeeMoreUncle and MV supplements . View all 60 products »
Sort by
Research
180-210 / 1000+ results
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Low-dose finasteride in benign prostatic hyperplasia: a comprehensive narrative review of efficacy, safety, and preventative potential
Finasteride 1 mg may help prevent prostate issues, but more research is needed to confirm its benefits.
research What is the best treatment for androgenic alopecia?
Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
research What is the best treatment for androgenic alopecia?
Dutasteride 0.5 mg/day is the best treatment for male pattern baldness.
research An Interventional, Comparative, Prospective Study to Determine Optimum Concentration of Intralesional Triamcinolone Acetonide in Treatment of Alopecia Areata
2.5 mg/ml of triamcinolone acetonide is more effective for treating alopecia areata.
research Oral Minoxidil 2.5mg vs 5mg for Male Androgenetic Alopecia: A Double-Blind Randomized Clinical Trial.
Both 2.5 mg and 5 mg doses of oral minoxidil are effective for hair regrowth in men with hair loss.
research Comparative Efficacy of Minoxidil and 5‐Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta‐Analysis Study of Current Empirical Evidence
Dutasteride 0.5 mg/day is the most effective treatment for male pattern hair loss.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research The impact of monotherapies for male androgenetic alopecia: A network meta‐analysis study
"Dutasteride 0.5 mg daily is the most effective treatment for male hair loss."
research Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]
Minoxidil 0.25 mg with spironolactone 25 mg reduces hair loss and improves hair density in women.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research Romatoid Artritli Hastalarda Metotreksat Toksisitesini Önlemede Yüksek Doz Günlük Folat Desteğine Karşın Düşük Doz Haftalık Folat Desteğinin Etkileri
Weekly 5 mg folate is enough to prevent methotrexate toxicity in rheumatoid arthritis patients.
research Therapies for onychomycosis: A systematic review and network metaanalysis of mycologic cure
Terbinafine 250 mg is the most effective treatment for fungal nail infections.
research How safe and effective is finasteride for hair loss in postmenopausal women?
Finasteride at 1 mg daily doesn't help hair loss in postmenopausal women and has similar side effects to a placebo.
research IMPLICAÇÕES DA TOMA CRÓNICA DA FINASTERIDE PARA A ALOPÉCIA ANDROGENÉTICA NO CARCINOMA DA PRÓSTATA
Chronic use of 1 mg/day finasteride for hair loss may delay prostate cancer diagnosis by lowering PSA levels.
research P163 : Clinical efficacy of 2.5mg/day finasteride in female pattern hair loss
2.5 mg/day finasteride effectively treats female pattern hair loss.
research Influence of finasteride treatment on metabolic profile of men with androgenetic alopecia
Taking 1 mg finasteride for a year reduces dihydrotestosterone levels in men with early hair loss, but doesn't change their metabolic state.
research Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
research A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome
The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research Mechanistic Approach on the Pulmonary Oxido-Inflammatory Stress Induced by Cobalt Ferrite Nanoparticles in Rats
Daily intake of 0.5 or 5 mg cobalt ferrite nanoparticles can harm lungs through oxidative and inflammatory stress.
research Acute and 30-day oral toxicity studies of a novel coccidiostat – ethanamizuril
Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
research Pantothenic Acid Deficiency in Baby Pigs
Young pigs need 10-20 mg of calcium pantothenate daily to fully recover from pantothenic acid deficiency.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research Efficacy of intralesional betamethasone versus triamcinolone acetonide in the treatment of alopecia areata
Triamcinolone acetonide and betamethasone 1.75 mg/ml are both effective for treating alopecia areata.
research Safety profile of CAP7.1 obtained during Phase I Trial in adult patients with refractory malignancies
CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
research Phase I Clinical Testing Antimalarial Drugs.
Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.